||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Circassia Share Discussion Threads
Showing 901 to 924 of 925 messages
|From the DJN report -
"The deal is expected to improve earnings for Circassia after one year and to be broadly cash neutral for three years, then cash generative."|
|Silly me, I looked at that chart assumed AIM.|
|Forget AIM. That's irrelevant to the investment case|
|Have to put it down to the vagaries of the AIM market.|
|Your guess is as good as mine.
it looks like a change in direction away from allergies.
either way the market loves today's news and I bet the agreement suits both parties
other than that, I am clueless...|
|It will cost CIR up to $230m, plus royalties, and Circassia will make R&D contributions of up to US$62.5 million payable to AstraZeneca as deferred payments.|
|Interesting, but why is it going up. CIR are buying the rights from AStraZeneca to sell two AstraZeneca products not the other way around.|
|Interesting news this morning|
|Nice r n s watch it grow|
|This is not making any recovery and serves as a reminder of the risks in this type of investment. Probably better to invest via a Fund to spread risk.|
|Circassia Pharmaceuticals extended Tuesday’s rebound
23rd June 2016
Circassia Pharmaceuticals, which on Monday tumbled more than 60 per cent after its cat allergy trial collapsed, extended Tuesday’s rebound, climbing 8.7 per cent, or 8.5p to 105.5p.|
|Peel Hunt said: Circassia uncertainty overhang medium-term unless a strategic bid emerges.
21st June 2016
|RBC Capital Markets, Peel Hunt Circassia slashed after poor test results - http://www.directorstalk.com/circassia-slashed-poor-test-results/ … - #CIR|
|Tempus in today's Times says its a buy.
When Circassia came to the market in 2014 at 310p a share, it was seen as the owner of a promising but unproven treatment for allergies, including hay fever. En route the company paid £239 million for a couple of companies making treatments for asthma and pulmonary disease, raising fresh funds at 288p a share. The first widescale trials of that allergy treatment for people allergic to cats have been an unmitigated disaster. Put simply, sufferers given the treatment did well but so did those given a placebo. This is frankly baffling. Circassia is giving up trials of the same treatment for sufferers of hay fever and those allergic to ragweed, though two others are sufficiently well advanced that there is no point in abandoning them. The conclusion of these may give an idea why the feline trials went so badly and whether the treatment has any value whatsoever.
This leaves the company with those asthma products, several of which are on the market. If the study was baffling, the market’s response was equally so. Circassia shares lost two thirds of their value, falling 179¼p to 91p. This gives it a market capitalisation of £257 million. Tot up the cost of those acquisitions and the cash in the bank and you get to £379 million. This suggests that the fall in the price is wildly overdone, assuming those businesses bought have the value ascribed to them, with the original allergy treatment assigned no value whatsoever.
Any biotech company is always going to be speculative, but this looks a good gamble.
MY ADVICE Buy
WHY Risky, but the share price fall looks overdone|
|Dead cat bounce.......|
|Numis said: Circassia Pharmaceuticals has collapsed 64%
20th June 2016
|Can't see this bouncing till the low 50's|
|Oh dear looks like 40p is on the cards cash at the bank valuation.|
|Also Woody sells he BT stake why?|
|Never admit that you were wrong or the game's all over
|will this bounce?|
|Oh dear, Woody's lost another £100m of other people's money|